MENAC: The Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia trial

MENAC is a large-scale open randomised phase III, multimodal intervention trial. 

 

 

 

 

Primary objective

To establish whether a multimodal intervention is effective in treating cachexia. This will be assessed after 2 cycles of chemotherapy (study endpoint -between 6 -9 weeks) by measuring weight. Importantly, benefits of trial will set a foundation for future nutritional and physical intervention for patients undergoing chemotherapy, an area that today is regularly neglected.

Secondary objectives

To examine the effect of a multimodal intervention for cancer cachexia on muscle mass (CT at L3) and physical activity (ActivPAL).

Patients

  • Diagnosis of lung cancer, pancreatic cancer or cholangiocarcinoma
  • Due to commence anti-cancer therapy

Patients and recruitment

A total of 240 patients will be recruited from out-patient oncology clinics at multiple sites in Europe, Canada and Australia.

The trial is open for inclusion at 12 centers in Norway, UK, Canada, Germany and Switzerland. By August 2018, 91 patients are enrolled in the trial. 

PIs: Professor Stein Kaasa, NTNU/Oslo University Hospital and Professor Marie Fallon, University of Edinburgh. 

For more information, or if your centre is interested in recruiting patients, please contact trial coordinator Inger Storaker (inger.storaker@ntnu.no).

 

Wed, 22 Aug 2018 13:23:30 +0200